| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA523: Midostaurin for untreated acute myeloid leukaemia |
|
Medicine details |
|
| Medicine name | midostaurin (Rydapt®) |
| Formulation | 25 mg soft capsule |
| Reference number | 1095 |
| Indication | In combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia who are FLT3 mutation positive |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 20/04/2018 |
| NICE guidance | |